Meeting NewsPerspective
September 10, 2017
MADRID — Nivolumab alone or in combination with ipilimumab as second- or third-line treatment demonstrated encouraging activity in patients…
Meeting NewsPerspective
September 10, 2017
MADRID — The addition of abemaciclib to endocrine therapy extended PFS and improved response rates among postmenopausal women with hormone…
Meeting NewsPerspective
September 10, 2017
MADRID — The addition of ramucirumab to docetaxel conferred a small but statistically significant PFS benefit for patients with advanced or…
Meeting News
September 9, 2017
MADRID — CT scan-based follow-up provided no significant survival benefit for patients who underwent complete resection for non-small cell lung…
Meeting NewsPerspective
September 9, 2017
MADRID — Adjuvant treatment with imatinib improved outcomes among patients with high-risk gastrointestinal stromal tumors, according to final…
Meeting News
September 9, 2017
MADRID — The addition of durvalumab to nab-paclitaxel slightly improved PFS and also improved response rates among patients with nonsquamous…
Meeting News
September 9, 2017
MADRID — The addition of pembrolizumab to pemetrexed and carboplatin for first-line therapy extended survival and improved response rates among…
Meeting NewsPerspective
September 9, 2017
MADRID — First-line osimertinib prolonged PFS by 54% compared with standard therapy among patients with EGFR-positive advanced non-small cell…
Meeting News
September 8, 2017
MADRID — Pembrolizumab demonstrated promising activity in patients with pretreated recurrent or metastatic gastric or gastroesophageal junction…
Meeting News
September 8, 2017
MADRID — The addition of abiraterone acetate plus prednisone to androgen deprivation therapy improved health-related quality of life among men…